Consensus statement on the current pharmacological prevention and management of heart failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35908234/
▪Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to prevent hospitalisation for heart failure in type 2 diabetes mellitus can be extended to patients with multiple cardiovascular risk factors, albuminuric chronic...
Main recommendations: Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to prevent hospitalisation for heart failure in type 2 diabetes mellitus can be extended to patients with multiple cardiovascular risk factors, albuminuric chronic kidney disease, or atherosclerotic cardiovascular disease ….
Share
Impact of Non-cardiac Comorbidities on Long-Term Clinical Outcomes and Health Status After Acute Heart Failure in China
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.883737/full
BackgroundIndividual non-cardiac comorbidities are prevalent in HF; however, few studies reported how the aggregate burden of non-cardiac comorbidities affects long-term outcomes, and it is unknown whether this burden is associated...
Conclusion: Among patients hospitalized with HF in this study, a higher burden of non-cardiac comorbidities was significantly associated with worse health-related QoL (HRQoL), increased risks of death, and rehospitalization post-discharge. The findings highlight the need to address the management of comorbidities effectively in standardized HF...
Share
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction - Cardiovascular Drugs and Therapy
Source : https://link.springer.com/article/10.1007/s10557-022-07371-7
Results from DELIVER trial and publication of EMPEROR-Preserved with sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure (HF) with ejection fraction (EF) > 40% represent a significant step forward in...
Relevance: Results from DELIVER trial and publication of EMPEROR-Preserved with sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure (HF) with ejection fraction (EF) > 40% represent a significant step forward in the treatment of HF with preserved EF (HFpEF). However, detailed analysis and attenuation of effect...
Share
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials
Source : https://www.medsci.org/v19p1118.htm
Int J Med Sci 2022; 19(7):1118-1121. doi:10.7150/ijms.72772 This issue Review Bo Liang 1,2, Ning Gu 3 1. Nanjing University of Chinese Medicine, Nanjing, China.2. Department of Cardiology, The Second Affiliated...
Relevance: Here, we summarize the latest and current understanding of the management for patients with established heart failure and type 2 diabetes mellitus and further present contemporary treatment options, sodium-glucose co-transporter-2 inhibitor, for these particular populations.
Share
Association between Empagliflozin Use and Electrocardiographic Changes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35892445/
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use...
Conclusion: We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.
Share
-
Heart Failure Connect3yrKey Points • Source: Clinics and Practice • Relevance: “Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) Show More